Want to join the conversation?
$JNJ's unit Janssen Research & Development said the U.S. Food and Drug Administration (FDA) has granted a Breakthrough Therapy Designation for use in combination with standard of care regimens for patients with multiple myeloma. Multiple myeloma is incurable blood cancer that occurs when malignant plasma cells grow uncontrollably in bone marrow.
$YHOO is reporting today after market close. Nobody cares about this stock.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.